Gold prices just lower; monthly gains on track
Dan Paterson, the President and CEO of Verastem, Inc. (NASDAQ:VSTM), recently sold a portion of his holdings in the company. The transaction comes as the stock has experienced a significant 11% decline over the past week, according to InvestingPro data. According to a filing with the Securities and Exchange Commission, Paterson sold 244 shares of common stock on March 17, 2025, at a price of $6.95 per share, totaling $1,695. This transaction was executed to satisfy statutory withholding requirements related to the vesting of restricted stock units. Following this sale, Paterson retains ownership of 346,479 shares in the company. Investors should note that Verastem is scheduled to report earnings in just two days, with analysts maintaining a strong buy consensus on the stock despite its recent volatility.
In other recent news, Verastem has been the subject of several notable developments. The company has received a Buy rating from BTIG, with an increased price target from $13.00 to $20.00, following the FDA’s acceptance of its New Drug Application for Avutometinib combined with Defactinib. This treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer is now under priority review, with a decision expected by June 30, 2025. Meanwhile, Mizuho (NYSE:MFG) Securities reiterated an Outperform rating with a $9.00 target, citing strategic priorities and upcoming clinical catalysts as key reasons for their positive outlook. Verastem’s financial restructuring efforts, including debt refinancing, have been highlighted as strategic moves to bolster stability and growth potential.
Additionally, BTIG analysts have expressed optimism about Verastem’s KRASG12D inhibitor program, which has shown promising results in early trials for advanced pancreatic and non-small cell lung cancer. The company has also entered into a partnership with IQVIA to support the launch of its treatments for low-grade serous ovarian cancer. In terms of leadership, Verastem has appointed Matthew E. Ros as Chief Operating Officer, bringing extensive biotech experience to the role. B.Riley analysts have maintained a Buy rating, noting that recent data from GenFleet Therapeutics’ draft application supports the potential of Verastem’s KRAS G12D inhibitor. These developments underscore Verastem’s ongoing efforts to advance its pipeline and transition to a commercial-stage company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.